AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00541359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01142323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: 160 mg po daily
Study NCT04076072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Utravit High-Speed 10000 cpm Beveled Probe
Description: This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
Study NCT04076072 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm
Description: This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
Study NCT04606511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Circumference tape measurements
Description: centimeter and volume criterias
Study NCT04606511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Indocyanine green lymphangiography
Description: Presence of dermal backflow
Study NCT04606511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bioimpedance spectroscopy
Description: 7.5 and 10 L-DEX criterias
Study NCT02809261 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided perineural injection with normal saline
Description: Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
Study NCT02809261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline is safe for perineural injection.
Study NCT02809261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Dextrose
Description: 5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
Study NCT04606511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Symptom score
Description: using lymph-icf, DASH and SF-36 questionnaires
Study NCT00911664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Weekly dose of 5600 IU (800 IU per day)
Study NCT00911664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No supplementation
Description: Control
Study NCT00911664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Weekly dose of 11,200 IU (1600 IU per day)
Study NCT01032785 — intervention group
Intervention type: DEVICE
Intervention: no interventions
Description: no interventions
Study NCT03969433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMSi Porti
Description: Data collections
Study NCT01872676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spine manipulation
Study NCT01872676 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manipulation sham
Study NCT02408653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Study NCT02408653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Study NCT03969433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloomlife sensor
Description: Data collections
Study NCT00259805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 given as an IV infusion once weekly for four doses
Study NCT03736577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug reviews with NorGeP-NH
Description: Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
Study NCT03245658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC and CBD Mixture
Description: Individually titrated doses on daily basis
Study NCT01717313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 25 mg capsule administered orally once a week.
Study NCT01717313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Omarigliptin
Description: Placebo to omarigliptin capsule administered orally once a week
Study NCT01717313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
Study NCT01717313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
Study NCT01717313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to metformin
Description: During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
Study NCT01717313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
Study NCT01717313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
Study NCT04352062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT04352062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04352062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole 40mg
Description: pantoprazole 2 x 40mg
Study NCT04352062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: Amoxicillin 2 x 1000mg
Study NCT04352062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin 500mg
Description: Levofloxacin 2 x 500mg
Study NCT01090245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management: voucher/monetary incentives for treatment attendance
Description: Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
Study NCT01090245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
Study NCT00075608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
Study NCT00075608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140-200 mcg/kg IV over two days
Study NCT00075608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: infusion of previously collected stem cells on Day 0
Study NCT00075608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell infusion
Description: infusion of previously collected stem cells on Day 0
Study NCT01446445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir/ Valganciclovir according to SPC
Description: Doses according to Summaries of Product Characteristics (SPC)
Study NCT01446445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir/ Valganciclovir according to PK model
Description: Doses according to population pharmacokinetic model
Study NCT03438032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy with lavage
Description: During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
Study NCT00492401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00492401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01613820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
Study NCT01613820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
Study NCT03988374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque, gingivitis, and bleeding.
Study NCT00956540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deflating tracheal cuff
Description: Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
Study NCT00956540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deflating tracheal cuff 2
Description: Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
Study NCT00447330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Description: Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin.
Study NCT03848091 — intervention group
Intervention type: OTHER
Intervention: Antibiotic pretreatment
Description: a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
Study NCT00671593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: House Dust Mite
Description: Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml
Study NCT00671593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
Study NCT02786043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine Hydrochloride
Description: 1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
Study NCT03681821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model (TTM)-based Intervention
Description: Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
Study NCT02966483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TaTME
Description: Transanal Total Mesorectal Excision
Study NCT02966483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LpTME
Description: Conventional Laparoscopic Total Mesorectal Excision
Study NCT03930186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration
Study NCT03930186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Therapy
Description: Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
Study NCT01365520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
Study NCT01330121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist Counseling
Description: Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic \& non-glycemic goal levels Explaining the importance of compliance with medications \& appointments Educating on the basics of nutrition and physical activity
Study NCT00492401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00492401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT00492401 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study NCT00492401 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study NCT00492401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT00492401 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies
Study NCT00492401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Description: Correlative studies
Study NCT00615706 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT00328263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285 and Lactobacillus casei
Description: One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
Study NCT00328263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
Study NCT03634215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fibrinogen plasma concentration, coagulation factor XIII activity
Description: blood sampling for a routine coagulation test
Study NCT01810991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Nd:YAG 1440nm Laser
Study NCT05028023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation - supplemental high flow oxygen administration by an apneic way
Description: In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
Study NCT02421120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: 1 hour intravenous infusion
Study NCT00882713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
Study NCT02852694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
Study NCT02852694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
Study NCT02852694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
Study NCT02852694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine / 6 Mercaptopurine
Description: Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
Study NCT03159754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Appendectomy
Description: Removal of the appendix within 24 hours of admission
Study NCT03159754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval Appendectomy
Description: Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
Study NCT03159754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
Study NCT00987051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection of sentinel node
Description: Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
Study NCT01623778 — intervention group
Intervention type: DRUG
Intervention: Interferon Alfa-2a add on ADV
Description: Interferon add on ADV for 48 weeks
Study NCT00748566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone HCL (oral)
Description: Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
Study NCT01466894 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM 124-E
Description: Tablets orally twice a day for 24 weeks
Study NCT01466894 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets orally twice daily for 24 weeks
Study NCT00354159 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)
Description: Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.